Epidermolysis Bullosa Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

Epidermolysis Bullosa companies are Phoenicis Therapeutics, Zikani Therapeutics, BioMendics, LLC, BPGbio Inc., Castle Creek Biosciences, InMed Pharmaceuticals Inc., Phoenix Tissue Repair, Inc., Castle Creek Biosciences, LLC., Abeona Therapeutics, RHEACELL, Abeona Therapeutics, Inc, and others.
(Albany, United States) "Epidermolysis Bullosa Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epidermolysis Bullosa Market.

The Epidermolysis Bullosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample page @ Epidermolysis Bullosa Pipeline Outlook [https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Epidermolysis Bullosa Pipeline Report:

- As per DelveInsight's assessment, globally, Epidermolysis Bullosa pipeline constitutes 25+ key companies continuously working towards developing 25+ Epidermolysis Bullosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

- Epidermolysis Bullosa Companies across the globe are diligently working toward developing novel Epidermolysis Bullosa treatment therapies with a considerable amount of success over the years.

- Epidermolysis Bullosa companies working in the treatment market are Phoenicis Therapeutics, Zikani Therapeutics, BioMendics, LLC, BPGbio Inc., Castle Creek Biosciences, InMed Pharmaceuticals Inc., Phoenix Tissue Repair, Inc., Castle Creek Biosciences, LLC., Abeona Therapeutics, RHEACELL, Abeona Therapeutics, Inc, and others, are developing therapies for the Epidermolysis Bullosa treatment

- Emerging Epidermolysis Bullosa therapies such as - PTD 003, ZKN 013, TolaSure, BP 31510, D-Fi (FCX-007), INM-755, PTR-01, FCX-007, EB-101, BCB5+ MSCs, EB 101, and others are expected to have a significant impact on the Epidermolysis Bullosa market in the coming years.

- In Oct 2024, Abeona Therapeutics, Inc. initiated a trial titled, "A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated Patients". A Multicenter, open-label, single-arm Phase 3b safety study of one-time surgical application of up to 8 autologous, gene-corrected keratinocyte sheets (EB-101) for the treatment of RDEB wounds in approximately 10-12 patients

Epidermolysis Bullosa Overview

Epidermolysis Bullosa (EB) is a rare genetic disorder that causes extreme skin fragility, leading to blistering, erosions, and chronic wounds from minor friction or trauma. It is classified into four main types-EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome-each varying in severity based on the affected skin layers. EB is caused by mutations in genes encoding structural proteins like keratins, collagens, and laminins, which are crucial for skin integrity.

Epidermolysis Bullosa Symptoms range from mild blistering to severe, life-threatening complications. Patients with severe forms may develop extensive skin and mucosal erosions, scarring, nail deformities, contractures, and increased risk of squamous cell carcinoma. Internal complications, including esophageal strictures, malnutrition, and infections, further impact quality of life.

Epidermolysis Bullosa Diagnosis involves clinical evaluation, genetic testing, and skin biopsy with immunofluorescence mapping. Currently, there is no cure, and treatment focuses on wound care, infection prevention, pain management, and supportive therapies. Emerging treatments, such as gene therapy, protein replacement, stem cell therapy, and CRISPR-based approaches, hold promise for improving outcomes. Multidisciplinary care, patient education, and advancements in regenerative medicine are crucial in managing Epidermolysis Bullosa, enhancing patient survival and quality of life.

Get a Free Sample PDF Report to know more about Epidermolysis Bullosa Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Epidermolysis Bullosa Drugs Under Different Phases of Clinical Development Include:

- PTD 003: Phoenicis Therapeutics

- ZKN 013: Zikani Therapeutics

- TolaSure BioMendics, LLC

- BP 31510: BPGbio Inc.

- D-Fi (FCX-007): Castle Creek Biosciences

- INM-755: InMed Pharmaceuticals Inc.

- PTR-01: Phoenix Tissue Repair, Inc.

- FCX-007: Castle Creek Biosciences, LLC.

- EB-101: Abeona Therapeutics

- BCB5+ MSCs: RHEACELL

Route of Administration

Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Molecule Type

Products have been categorized under various Molecule types, such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

Epidermolysis Bullosa Pipeline Therapeutics Assessment

- Epidermolysis Bullosa Assessment by Product Type

- Epidermolysis Bullosa By Stage and Product Type

- Epidermolysis Bullosa Assessment by Route of Administration

- Epidermolysis Bullosa By Stage and Route of Administration

- Epidermolysis Bullosa Assessment by Molecule Type

- Epidermolysis Bullosa by Stage and Molecule Type

DelveInsight's Epidermolysis Bullosa Pipeline Report covers around 25+ products under different phases of clinical development like-

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I)

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Further Epidermolysis Bullosa product details are provided in the report. Download the Epidermolysis Bullosa pipeline report to learn more about the emerging Epidermolysis Bullosa therapies @ Epidermolysis Bullosa Treatment Market [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the Epidermolysis Bullosa Therapeutics Market include: Key companies developing therapies for Epidermolysis Bullosa are - Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Aegle Therapeutics, Phoenix Tissue Repair, Inc., Lenus Therapeutics, LLC, Wings Therapeutics Inc., Krystal Biotech, Inc., Onconova Therapeutics, Inc., InMed Pharmaceuticals Inc., Constant Therapeutics, Kangstem Biotech, ProQR Therapeutics, Ishin Pharmaceutical , and others.

Epidermolysis Bullosa Pipeline Analysis:

The Epidermolysis Bullosa pipeline report provides insights into

- The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.

- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.

- Epidermolysis Bullosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

- Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.

Download Sample PDF Report to know more about Epidermolysis Bullosa drugs and therapies @ Epidermolysis Bullosa Clinical Trials and Advancements [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Epidermolysis Bullosa Pipeline Market Drivers

Increasing prevalence of Epidermolysis bullosa, increasing Clinical trials for the treatment of EB are some of the important factors that are fueling the Epidermolysis Bullosa Market.

Epidermolysis Bullosa Pipeline Market Barriers

High cost associated with the treatment and diagnosis of Epidermolysis bullosa, side effects associated with the treatment and other factors are creating obstacles in the Epidermolysis Bullosa Market growth.

Scope of Epidermolysis Bullosa Pipeline Drug Insight

- Coverage: Global

- Key Epidermolysis Bullosa Companies: Phoenicis Therapeutics, Zikani Therapeutics, BioMendics, LLC, BPGbio Inc., Castle Creek Biosciences, InMed Pharmaceuticals Inc., Phoenix Tissue Repair, Inc., Castle Creek Biosciences, LLC., Abeona Therapeutics, RHEACELL, Abeona Therapeutics, Inc, and others

- Key Epidermolysis Bullosa Therapies: PTD 003, ZKN 013, TolaSure, BP 31510, D-Fi (FCX-007), INM-755, PTR-01, FCX-007, EB-101, BCB5+ MSCs, EB 101, and others

- Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies

- Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers

Request for Sample PDF Report for Epidermolysis Bullosa Pipeline Assessment and clinical trials @ Epidermolysis Bullosa Companies and Medication [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1 Epidermolysis Bullosa Report Introduction

2 Epidermolysis Bullosa Executive Summary

3 Epidermolysis Bullosa Overview

4 Epidermolysis Bullosa- Analytical Perspective In-depth Commercial Assessment

5 Epidermolysis Bullosa Pipeline Therapeutics

6 Epidermolysis Bullosa Late Stage Products (Phase II/III)

7 Epidermolysis Bullosa Mid Stage Products (Phase II)

8 Epidermolysis Bullosa Early Stage Products (Phase I)

9 Epidermolysis Bullosa Preclinical Stage Products

10 Epidermolysis Bullosa Therapeutics Assessment

11 Epidermolysis Bullosa Inactive Products

12 Company-University Collaborations (Licensing/Partnering) Analysis

13 Epidermolysis Bullosa Key Companies

14 Epidermolysis Bullosa Key Products

15 Epidermolysis Bullosa Unmet Needs

16 Epidermolysis Bullosa Market Drivers and Barriers

17 Epidermolysis Bullosa Future Perspectives and Conclusion

18 Epidermolysis Bullosa Analyst Views

19 Appendix

20 About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epidermolysis-bullosa-clinical-trials-and-pipeline-2025-ema-pdma-fda-approvals-medication-nda-approval-therapies-roa-moa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.